Keros Therapeutics 第四季度每股收益为$(1.14),低于预期$(0.96),销售额为304万美元,低于预期1542万美元

财报速递
27 Feb

Keros Therapeutics(LENZ)第四季度每股收益$(1.14),低于预期$(0.96),销售额304万美元,低于预期1542万美元



以上内容来自Benzinga Earnings专栏,原文如下:

Keros Therapeutics Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10